| Procter & Gamble Health announced that the Company plans to source injections portfolio of its products from a contract manufacturer, hence the Company shall discontinue production of injections at its manufacturing plant in Goa effective 30 September 2023.
The injections portfolio, procured from the Company's manufacturing facility at Goa, accounted for revenue of Rs. 102.92 crore during the financial year 2022-23, constituting 8.37% of the Company's total revenue. Discontinuation of production at Company's plant in Goa,
shall not have an impact on continuity of sale of injections by the Company, as the products will be sourced from a contract manufacturer.
The Company is outsourcing manufacturing of the injections portfolio, with an intent to achieve cost efficiency and supply optimization. |